Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting Autophagy in Breast Cancer.
Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, Fusco G, Capozzi M, Gioia GD, Budillon A, De Laurentiis M. Cocco S, et al. Among authors: di rella f. Int J Mol Sci. 2020 Oct 22;21(21):7836. doi: 10.3390/ijms21217836. Int J Mol Sci. 2020. PMID: 33105796 Free PMC article. Review.
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.
Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A. Perrone F, et al. Among authors: di rella f, di maio m. Ann Oncol. 2015 Apr;26(4):675-682. doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8. Ann Oncol. 2015. PMID: 25488686 Free article. Clinical Trial.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M, Bonfadini C, Lorusso V, Cilenti G, Di Rella F, Altavilla G, Otero M, Ardizzoia A, Marchetti P, Peverelli G, Amoroso D, Vecchio S, Fiorio E, Orecchia S. De Laurentiis M, et al. Among authors: di rella f. Support Care Cancer. 2018 Dec;26(12):4021-4029. doi: 10.1007/s00520-018-4259-1. Epub 2018 Jun 25. Support Care Cancer. 2018. PMID: 29943152
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C. Perrone F, et al. Among authors: di rella f. Eur J Cancer. 2019 Sep;118:178-186. doi: 10.1016/j.ejca.2019.05.004. Epub 2019 Jun 1. Eur J Cancer. 2019. PMID: 31164265 Clinical Trial.
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues.
Conforti A, Schettini F, Vallone R, Di Rella F, De Rosa P, De Santo I, Giuliano M, Arpino G, Lauria R, De Placido S, Caputo R, De Laurentiis M, Nazzaro G, De Placido G, Locci M, Alviggi C. Conforti A, et al. Among authors: di rella f. Breast J. 2019 Nov;25(6):1310-1311. doi: 10.1111/tbj.13474. Epub 2019 Jul 23. Breast J. 2019. PMID: 31338934 No abstract available.
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, Pagliuca M, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M. Caputo R, et al. Among authors: di rella f. Future Oncol. 2023 Aug;19(24):1695-1708. doi: 10.2217/fon-2023-0361. Epub 2023 Aug 22. Future Oncol. 2023. PMID: 37605877 Review.
Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study.
Caminiti C, Maglietta G, Arenare L, Di Liello R, Migliaccio G, Barberio D, De Laurentiis M, Di Rella F, Nuzzo F, Pacilio C, Iodice G, Orditura M, Ciardiello F, Di Bella S, Cavanna L, Porta C, Giovanardi F, Ripamonti CI, Bilancia D, Aprile G, Ruelle T, Diodati F, Piccirillo MC, Iannelli E, Pinto C, Perrone F. Caminiti C, et al. Among authors: di rella f. Breast. 2024 Oct;77:103781. doi: 10.1016/j.breast.2024.103781. Epub 2024 Jul 20. Breast. 2024. PMID: 39059033 Free PMC article.
46 results